This systematic review and meta-analysis evaluated the association between DPP-4 inhibitors and gallbladder or biliary diseases in patients with type 2 diabetes. It analyzed data from 82 randomized controlled trials involving over 100,000 participants. The analysis found that DPP-4 inhibitors were associated with a small increased risk of gallbladder or biliary diseases and cholecystitis compared to placebo or other antidiabetes drugs. The risk was higher with longer durations of DPP-4 inhibitor treatment of 26 weeks or more. DPP-4 inhibitors also showed a higher risk of cholecystitis compared to SGLT-2 inhibitors, though a similar risk as GLP-1 receptor agonists. The overall absolute risk increase was
This document discusses treatment options after metformin for type 2 diabetes, comparing sulfonylureas and gliptins. It provides the following key points:
1. Sulfonylureas are more effective at reducing HbA1c levels and achieving glycemic control targets compared to gliptins. They lower HbA1c by 1-2% on average versus 0.5-1% for gliptins.
2. Studies show sulfonylureas may better preserve beta-cell function in the long-term compared to metformin or gliptins. They have been shown to enhance insulin secretion from beta and alpha cells.
3. While older studies linked sulfonylureas
DPP4 inhibitors have similarities such as sustained glucose lowering, minimal side effects, and weight neutrality. Differences include binding characteristics, with some binding longer to DPP4. Vildagliptin may provide better fasting glucose control due to maintaining overnight GLP1 levels. Vildagliptin has proven efficacy and safety in Ramadan fasting and has shown cardiovascular safety in clinical trials and real-world evidence, with no increased risk of heart failure unlike some other DPP4 inhibitors.
A 63-year-old man with type 2 diabetes and chronic kidney disease visited his doctor with complaints of increased fatigue and two episodes of hypoglycemia. He has a history of diabetes for 11 years and hypertension for 6.5 years. Laboratory tests showed uncontrolled diabetes with an HbA1c of 9.0% and declining renal function, with an eGFR of 51 mL/min/1.73m2 and a urinary albumin-to-creatinine ratio of 435 mg/g, indicating high risk of cardiovascular disease and progression of kidney disease. The patient is currently taking metformin, glimepiride, sitagliptin, and antihypertensive medications.
Effect of Dapagliflozin on Cardiovascular Risk Factors.pptxVenkataSurya12
Dapagliflozin is a SGLT2 inhibitor that was evaluated in a clinical trial involving 4,744 patients with heart failure to determine its effect on cardiovascular risk factors. The trial found that dapagliflozin was safer for patients and resulted in fewer adverse reactions compared to a placebo. It significantly reduced the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular events or renal death. Based on these results, dapagliflozin was approved under the brand name Forxiga for the treatment of heart failure and chronic kidney disease.
NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...JohnJulie1
This study analyzed medication use among patients with NAFLD and/or advanced fibrosis using NHANES 2017-2018 data. The following key points are summarized:
1. Patients with NAFLD or advanced fibrosis had higher rates of polypharmacy, with more medications and medication classes compared to those without these conditions.
2. While medication usage indicated higher risk of cardiovascular and metabolic issues associated with NAFLD, usage of GLP1 agonists and SGLT2 inhibitors was low among diabetics regardless of NAFLD status.
3. Diabetics with advanced fibrosis had fewer medications on average than those without advanced fibrosis, possibly due to disease progression effects, though access to beneficial therapies like G
This prsentation explains the use of biomarker with reference to an article: Accelerating Drug Develeopment using Biomarkers-Sitagliptin.
It was presented my my 2 friends and me. Hope it helps you guys.
This study investigated cardiovascular and gastrointestinal outcomes in clopidogrel users who were also taking proton pump inhibitors (PPIs) using a large cohort of patients in the Netherlands. The study found that clopidogrel users who were also taking PPIs had a 75% higher risk of cardiovascular events compared to clopidogrel-only users. However, the study had limitations such as channeling bias since PPI users had more risk factors, and residual confounding since important risk factors could not be adjusted for. While providing useful insights, the study's findings on the risks of PPI co-administration should be interpreted cautiously due to its limitations.
Diabetic kidney disease remains a major global health problem. Recent research has provided insights into the pathophysiology and has identified new diagnostic and therapeutic approaches. Several large clinical trials have shown that sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and endothelin receptor antagonists can reduce kidney disease progression and cardiovascular events in patients with diabetes and kidney disease. Ongoing trials are further evaluating combination therapies and the benefits of these agents in non-diabetic kidney disease and heart failure.
This document discusses treatment options after metformin for type 2 diabetes, comparing sulfonylureas and gliptins. It provides the following key points:
1. Sulfonylureas are more effective at reducing HbA1c levels and achieving glycemic control targets compared to gliptins. They lower HbA1c by 1-2% on average versus 0.5-1% for gliptins.
2. Studies show sulfonylureas may better preserve beta-cell function in the long-term compared to metformin or gliptins. They have been shown to enhance insulin secretion from beta and alpha cells.
3. While older studies linked sulfonylureas
DPP4 inhibitors have similarities such as sustained glucose lowering, minimal side effects, and weight neutrality. Differences include binding characteristics, with some binding longer to DPP4. Vildagliptin may provide better fasting glucose control due to maintaining overnight GLP1 levels. Vildagliptin has proven efficacy and safety in Ramadan fasting and has shown cardiovascular safety in clinical trials and real-world evidence, with no increased risk of heart failure unlike some other DPP4 inhibitors.
A 63-year-old man with type 2 diabetes and chronic kidney disease visited his doctor with complaints of increased fatigue and two episodes of hypoglycemia. He has a history of diabetes for 11 years and hypertension for 6.5 years. Laboratory tests showed uncontrolled diabetes with an HbA1c of 9.0% and declining renal function, with an eGFR of 51 mL/min/1.73m2 and a urinary albumin-to-creatinine ratio of 435 mg/g, indicating high risk of cardiovascular disease and progression of kidney disease. The patient is currently taking metformin, glimepiride, sitagliptin, and antihypertensive medications.
Effect of Dapagliflozin on Cardiovascular Risk Factors.pptxVenkataSurya12
Dapagliflozin is a SGLT2 inhibitor that was evaluated in a clinical trial involving 4,744 patients with heart failure to determine its effect on cardiovascular risk factors. The trial found that dapagliflozin was safer for patients and resulted in fewer adverse reactions compared to a placebo. It significantly reduced the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular events or renal death. Based on these results, dapagliflozin was approved under the brand name Forxiga for the treatment of heart failure and chronic kidney disease.
NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...JohnJulie1
This study analyzed medication use among patients with NAFLD and/or advanced fibrosis using NHANES 2017-2018 data. The following key points are summarized:
1. Patients with NAFLD or advanced fibrosis had higher rates of polypharmacy, with more medications and medication classes compared to those without these conditions.
2. While medication usage indicated higher risk of cardiovascular and metabolic issues associated with NAFLD, usage of GLP1 agonists and SGLT2 inhibitors was low among diabetics regardless of NAFLD status.
3. Diabetics with advanced fibrosis had fewer medications on average than those without advanced fibrosis, possibly due to disease progression effects, though access to beneficial therapies like G
This prsentation explains the use of biomarker with reference to an article: Accelerating Drug Develeopment using Biomarkers-Sitagliptin.
It was presented my my 2 friends and me. Hope it helps you guys.
This study investigated cardiovascular and gastrointestinal outcomes in clopidogrel users who were also taking proton pump inhibitors (PPIs) using a large cohort of patients in the Netherlands. The study found that clopidogrel users who were also taking PPIs had a 75% higher risk of cardiovascular events compared to clopidogrel-only users. However, the study had limitations such as channeling bias since PPI users had more risk factors, and residual confounding since important risk factors could not be adjusted for. While providing useful insights, the study's findings on the risks of PPI co-administration should be interpreted cautiously due to its limitations.
Diabetic kidney disease remains a major global health problem. Recent research has provided insights into the pathophysiology and has identified new diagnostic and therapeutic approaches. Several large clinical trials have shown that sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and endothelin receptor antagonists can reduce kidney disease progression and cardiovascular events in patients with diabetes and kidney disease. Ongoing trials are further evaluating combination therapies and the benefits of these agents in non-diabetic kidney disease and heart failure.
Antihyperglycemic effects of short term resveratrol supplementation in type 2...zanet1
1) The study examined the effects of short term resveratrol supplementation in patients with type 2 diabetes who were receiving standard antidiabetic treatment. 66 patients were randomly assigned to receive either 1 g per day of resveratrol or a placebo for 45 days.
2) Resveratrol treatment significantly decreased systolic blood pressure, fasting blood glucose, HbA1c, insulin, and insulin resistance compared to baseline. HDL was also significantly increased.
3) In contrast, the placebo group had slightly increased fasting glucose and LDL compared to baseline. Liver and kidney function markers were unchanged with resveratrol treatment.
EVALUATION OF GLYCEMIC RESPONSE OF ADDITION OF PIOGLITAZONE TO GLIBENCLAMIDE...Nani Karnam Vinayakam
Retrospective study of Antidiabetic drugs in Diabetes Mellitus patients. It help in for Pharmacy graduates, Pharm D Students, M Pharm -pharmacy practice students , hospital pharmacists & Clinical Pharmacists around the globe.
Linagliptin - Speaker training kit India final1234.pptxAmeetRathod3
Linagliptin is a DPP-4 inhibitor indicated for type 2 diabetes. It has a unique xanthine-based structure that allows for tight binding to DPP-4 and full 24-hour inhibition. Clinical trials involving over 6,000 patients across many countries demonstrated linagliptin's ability to significantly reduce HbA1c levels when used as monotherapy, in combination with metformin, or metformin and sulfonylurea, with a safety profile similar to placebo. Linagliptin's structure contributes to its sustained glycemic control and safety advantages over other DPP-4 inhibitors.
Alive pd protocol and descriptive paperGladys Block
Alive-PD is a fully automated tailored diabetes prevention program. This journal article describes its features, and describes the protocol of the randomized controlled trial.
Alive-PD protocol and descriptive paperGladys Block
The document describes a randomized controlled trial protocol to evaluate the effectiveness of a fully automated 1-year diabetes prevention program called Alive-PD. 340 subjects with pre-diabetes were randomized to either the Alive-PD intervention group (n=164) or a delayed-entry control group (n=176). The primary outcomes are changes in HbA1c and fasting glucose levels from baseline to 6 months. Secondary outcomes include changes in additional biometric measures at 3, 6, 9, and 12 months. The intervention involves weekly tailored goal setting, challenges, and other online interactions to encourage diet and physical activity changes to prevent diabetes progression. The trial will provide evidence on the efficacy of this web-based program in reducing gly
Diabetic nursing visits for better A1C control in patients Discussion.pdfsdfghj21
Diabetic nursing visits can help improve A1C control in patients through education on lifestyle changes, diet, medications, and monitoring. Studies have found uncontrolled diabetes leads to complications like eye, kidney and cardiovascular issues. Nurses play an important role in helping patients manage their diabetes tighter through regular visits focused on glycemic control.
A Little Bit of Everything, Quick & Snappy: Probiotics to Advances in the Car...PASaskatchewan
As pharmacists, you are rarely faced with a consistent patient population with similar problems and questions. More likely, each patient you interact with has unique and varied concerns that you must be ready to address in an instant. This session reflects the diversity of patients a pharmacist will face in day-to-day practice and covers a range of topics in a quick and snappy format. This session will cover the evidence as it relates to concurrent probiotic and antibiotic use, second line treatment for patients with type 2 diabetes, and explore new utilization strategies of using drugs traditionally used in the treatment of type 2 diabetes for patients with type 1 diabetes.
Early Phase Clinical Trials in Patients with Hepatic or Renal Impairment: Fro...SGS
Pharmacokinetic studies in renal or hepatic impaired subjects are often part of the Early Phase Clinical Pharmacology trial portfolio. For most of the drugs that are likely to be administered to patients with renal or hepatic impairment, including drugs that are not primarily excreted by kidney or primarily eliminated by hepatic metabolism/excretion, pharmacokinetics should be assessed in patients with renal or hepatic impairment to provide appropriate dosing recommendations. EMA and FDA guidances are there to support study design, conduct and data analysis, and should be viewed as recommendations. However, in practice, some key questions about design must still be discussed taking into consideration the detailed properties of the investigational drug. This presentation will discuss how the expertise and feasibility analysis are crucial to get valuable results and perform these trials in time.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Purpose: The purpose of this study was to compare the safety and efficacy of DPP-4 inhibitors versus sulfonylurea as adjunctive second-line therapy in patients with type 2 diabetes mellitus, inadequately controlled with metformin mono-therapy.
(PDF) Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. Available from: https://www.researchgate.net/publication/301553548_Safety_and_efficacy_of_dipeptidyl_peptidase-4_inhibitors_vs_sulfonylurea_in_metformin-based_combination_therapy_for_type_2_diabetes_mellitus_Systematic_review_and_meta-analysis#fullTextFileContent [accessed May 09 2020].
A Comprehensive Review of Teneligliptin on its Pharmacological, Pharmaceutica...BRNSSPublicationHubI
Teneligliptin is a DPP-4 inhibitor used to treat type 2 diabetes. It works by inhibiting the DPP-4 enzyme, prolonging the effects of incretin hormones and promoting insulin secretion. Studies show it effectively lowers blood glucose levels. It is available in tablet and combination formulations, offering flexibility. Analytical methods ensure its purity, stability, and consistent dosing. Its efficacy, formulations, and analysis make it a valuable treatment for managing diabetes.
Renal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdfHaramaya University
This randomized controlled trial evaluated the cardiovascular and renal outcomes of efpeglenatide, a weekly injectable GLP-1 receptor agonist, in patients with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus additional cardiovascular risk factors. A total of 4076 participants were randomly assigned to receive either efpeglenatide at doses of 4 or 6 mg or placebo. The primary outcome was the first occurrence of a major adverse cardiovascular event (MACE). Secondary outcomes included a composite renal outcome. During a median follow up of 1.81 years, MACE occurred in 7.0% of those receiving efpeglenatide versus 9.2% of those receiving placebo, meeting the criteria for
The document summarizes a clinical trial that assessed the efficacy and safety of liraglutide compared to placebo for treating type 2 diabetes in children and adolescents when added to metformin with or without basal insulin. The trial found that liraglutide was effective at improving glycemic control over 52 weeks compared to placebo, though it increased the frequency of gastrointestinal side effects. Specifically, glycated hemoglobin levels were reduced more in the liraglutide group compared to the placebo group at 26 weeks. Fasting plasma glucose and body weight were also lowered more by liraglutide, but the difference in BMI between groups was not statistically significant.
This document summarizes a review article about the effects of Dipeptidyl Peptidase-4 (DPP-4) inhibitors on pancreatic islet cell function in patients with type 2 diabetes. DPP-4 inhibitors work by blocking the enzyme DPP-4, which degrades the incretin hormones GLP-1 and GIP. This allows GLP-1 and GIP levels to increase after meals and stimulate insulin secretion while decreasing glucagon secretion. Studies in rodents and humans suggest that DPP-4 inhibitors may improve beta cell and alpha cell function. However, there is currently no evidence that DPP-4 inhibitors can durably preserve islet cell function after treatment is stopped in humans. Large
Teneligliptin the next generation gliptinAKSHATA RAO
Teneligliptin , one of the emerging gliptins have established its prowess among the gliptin giants like Sitagliptin Vildagliptin and Linagliptin. Proven to be safe in renally compromised patients, this one is to watch out for.
This document summarizes the results of a randomized, prospective, open-label clinical trial evaluating the efficacy and safety of Sulfad tablets for the management of non-alcoholic steatohepatitis (NASH) patients. The trial involved 100 patients taking Sulfad tablets for 3 months. Significant improvements were seen in liver enzymes and lipid profiles after 1, 2, and 3 months of treatment. No major safety issues were reported. The study concluded that Sulfad tablets were well-tolerated and effective for the management of NASH patients.
efficacy and safety of Sulfad tablets in the management of NASH
patients: A randomized ,prospective, open label, multi-center,
controlled, phase III clinical trial.
This document summarizes research on the efficacy and safety of the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) for the treatment of type 2 diabetes. It describes several clinical trials (DURATION studies) that evaluated exenatide QW and found it reduced HbA1c, fasting blood glucose, and body weight over 24-30 weeks. Adverse effects like nausea and diarrhea were less than other GLP-1RAs but injection site reactions were more common. Overall, the studies demonstrated the clinical efficacy of exenatide QW for type 2 diabetes treatment.
Dr. Praveen Balimane, senior staff fellow, Division of Clinical Pharmacology-1 at OCP/OTS/CDER/FDA, spoke during the Society for Laboratory Automation and Screening ADMET Special Interest Group Meeting on “Transporter Evaluation in Drug Development.”
Transporters, like CYPs, are being recognized as proteins that can play a pivotal role in dictating the ADME properties of drugs. A thorough understanding of potential roles of transporters in drug interactions and toxicity is important in drug development. The talk provided a high level overview of various transporter evaluation initiatives at the agency. Some of the topics discussed:
• On-going efforts on decision trees within the DDI guidance
• Novel emerging transporters impacting ADME
• Inter-play of hepatic transporters and liver-toxicity
• Inter-play of renal transporters and renal function
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Antihyperglycemic effects of short term resveratrol supplementation in type 2...zanet1
1) The study examined the effects of short term resveratrol supplementation in patients with type 2 diabetes who were receiving standard antidiabetic treatment. 66 patients were randomly assigned to receive either 1 g per day of resveratrol or a placebo for 45 days.
2) Resveratrol treatment significantly decreased systolic blood pressure, fasting blood glucose, HbA1c, insulin, and insulin resistance compared to baseline. HDL was also significantly increased.
3) In contrast, the placebo group had slightly increased fasting glucose and LDL compared to baseline. Liver and kidney function markers were unchanged with resveratrol treatment.
EVALUATION OF GLYCEMIC RESPONSE OF ADDITION OF PIOGLITAZONE TO GLIBENCLAMIDE...Nani Karnam Vinayakam
Retrospective study of Antidiabetic drugs in Diabetes Mellitus patients. It help in for Pharmacy graduates, Pharm D Students, M Pharm -pharmacy practice students , hospital pharmacists & Clinical Pharmacists around the globe.
Linagliptin - Speaker training kit India final1234.pptxAmeetRathod3
Linagliptin is a DPP-4 inhibitor indicated for type 2 diabetes. It has a unique xanthine-based structure that allows for tight binding to DPP-4 and full 24-hour inhibition. Clinical trials involving over 6,000 patients across many countries demonstrated linagliptin's ability to significantly reduce HbA1c levels when used as monotherapy, in combination with metformin, or metformin and sulfonylurea, with a safety profile similar to placebo. Linagliptin's structure contributes to its sustained glycemic control and safety advantages over other DPP-4 inhibitors.
Alive pd protocol and descriptive paperGladys Block
Alive-PD is a fully automated tailored diabetes prevention program. This journal article describes its features, and describes the protocol of the randomized controlled trial.
Alive-PD protocol and descriptive paperGladys Block
The document describes a randomized controlled trial protocol to evaluate the effectiveness of a fully automated 1-year diabetes prevention program called Alive-PD. 340 subjects with pre-diabetes were randomized to either the Alive-PD intervention group (n=164) or a delayed-entry control group (n=176). The primary outcomes are changes in HbA1c and fasting glucose levels from baseline to 6 months. Secondary outcomes include changes in additional biometric measures at 3, 6, 9, and 12 months. The intervention involves weekly tailored goal setting, challenges, and other online interactions to encourage diet and physical activity changes to prevent diabetes progression. The trial will provide evidence on the efficacy of this web-based program in reducing gly
Diabetic nursing visits for better A1C control in patients Discussion.pdfsdfghj21
Diabetic nursing visits can help improve A1C control in patients through education on lifestyle changes, diet, medications, and monitoring. Studies have found uncontrolled diabetes leads to complications like eye, kidney and cardiovascular issues. Nurses play an important role in helping patients manage their diabetes tighter through regular visits focused on glycemic control.
A Little Bit of Everything, Quick & Snappy: Probiotics to Advances in the Car...PASaskatchewan
As pharmacists, you are rarely faced with a consistent patient population with similar problems and questions. More likely, each patient you interact with has unique and varied concerns that you must be ready to address in an instant. This session reflects the diversity of patients a pharmacist will face in day-to-day practice and covers a range of topics in a quick and snappy format. This session will cover the evidence as it relates to concurrent probiotic and antibiotic use, second line treatment for patients with type 2 diabetes, and explore new utilization strategies of using drugs traditionally used in the treatment of type 2 diabetes for patients with type 1 diabetes.
Early Phase Clinical Trials in Patients with Hepatic or Renal Impairment: Fro...SGS
Pharmacokinetic studies in renal or hepatic impaired subjects are often part of the Early Phase Clinical Pharmacology trial portfolio. For most of the drugs that are likely to be administered to patients with renal or hepatic impairment, including drugs that are not primarily excreted by kidney or primarily eliminated by hepatic metabolism/excretion, pharmacokinetics should be assessed in patients with renal or hepatic impairment to provide appropriate dosing recommendations. EMA and FDA guidances are there to support study design, conduct and data analysis, and should be viewed as recommendations. However, in practice, some key questions about design must still be discussed taking into consideration the detailed properties of the investigational drug. This presentation will discuss how the expertise and feasibility analysis are crucial to get valuable results and perform these trials in time.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Purpose: The purpose of this study was to compare the safety and efficacy of DPP-4 inhibitors versus sulfonylurea as adjunctive second-line therapy in patients with type 2 diabetes mellitus, inadequately controlled with metformin mono-therapy.
(PDF) Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. Available from: https://www.researchgate.net/publication/301553548_Safety_and_efficacy_of_dipeptidyl_peptidase-4_inhibitors_vs_sulfonylurea_in_metformin-based_combination_therapy_for_type_2_diabetes_mellitus_Systematic_review_and_meta-analysis#fullTextFileContent [accessed May 09 2020].
A Comprehensive Review of Teneligliptin on its Pharmacological, Pharmaceutica...BRNSSPublicationHubI
Teneligliptin is a DPP-4 inhibitor used to treat type 2 diabetes. It works by inhibiting the DPP-4 enzyme, prolonging the effects of incretin hormones and promoting insulin secretion. Studies show it effectively lowers blood glucose levels. It is available in tablet and combination formulations, offering flexibility. Analytical methods ensure its purity, stability, and consistent dosing. Its efficacy, formulations, and analysis make it a valuable treatment for managing diabetes.
Renal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdfHaramaya University
This randomized controlled trial evaluated the cardiovascular and renal outcomes of efpeglenatide, a weekly injectable GLP-1 receptor agonist, in patients with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus additional cardiovascular risk factors. A total of 4076 participants were randomly assigned to receive either efpeglenatide at doses of 4 or 6 mg or placebo. The primary outcome was the first occurrence of a major adverse cardiovascular event (MACE). Secondary outcomes included a composite renal outcome. During a median follow up of 1.81 years, MACE occurred in 7.0% of those receiving efpeglenatide versus 9.2% of those receiving placebo, meeting the criteria for
The document summarizes a clinical trial that assessed the efficacy and safety of liraglutide compared to placebo for treating type 2 diabetes in children and adolescents when added to metformin with or without basal insulin. The trial found that liraglutide was effective at improving glycemic control over 52 weeks compared to placebo, though it increased the frequency of gastrointestinal side effects. Specifically, glycated hemoglobin levels were reduced more in the liraglutide group compared to the placebo group at 26 weeks. Fasting plasma glucose and body weight were also lowered more by liraglutide, but the difference in BMI between groups was not statistically significant.
This document summarizes a review article about the effects of Dipeptidyl Peptidase-4 (DPP-4) inhibitors on pancreatic islet cell function in patients with type 2 diabetes. DPP-4 inhibitors work by blocking the enzyme DPP-4, which degrades the incretin hormones GLP-1 and GIP. This allows GLP-1 and GIP levels to increase after meals and stimulate insulin secretion while decreasing glucagon secretion. Studies in rodents and humans suggest that DPP-4 inhibitors may improve beta cell and alpha cell function. However, there is currently no evidence that DPP-4 inhibitors can durably preserve islet cell function after treatment is stopped in humans. Large
Teneligliptin the next generation gliptinAKSHATA RAO
Teneligliptin , one of the emerging gliptins have established its prowess among the gliptin giants like Sitagliptin Vildagliptin and Linagliptin. Proven to be safe in renally compromised patients, this one is to watch out for.
This document summarizes the results of a randomized, prospective, open-label clinical trial evaluating the efficacy and safety of Sulfad tablets for the management of non-alcoholic steatohepatitis (NASH) patients. The trial involved 100 patients taking Sulfad tablets for 3 months. Significant improvements were seen in liver enzymes and lipid profiles after 1, 2, and 3 months of treatment. No major safety issues were reported. The study concluded that Sulfad tablets were well-tolerated and effective for the management of NASH patients.
efficacy and safety of Sulfad tablets in the management of NASH
patients: A randomized ,prospective, open label, multi-center,
controlled, phase III clinical trial.
This document summarizes research on the efficacy and safety of the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) for the treatment of type 2 diabetes. It describes several clinical trials (DURATION studies) that evaluated exenatide QW and found it reduced HbA1c, fasting blood glucose, and body weight over 24-30 weeks. Adverse effects like nausea and diarrhea were less than other GLP-1RAs but injection site reactions were more common. Overall, the studies demonstrated the clinical efficacy of exenatide QW for type 2 diabetes treatment.
Dr. Praveen Balimane, senior staff fellow, Division of Clinical Pharmacology-1 at OCP/OTS/CDER/FDA, spoke during the Society for Laboratory Automation and Screening ADMET Special Interest Group Meeting on “Transporter Evaluation in Drug Development.”
Transporters, like CYPs, are being recognized as proteins that can play a pivotal role in dictating the ADME properties of drugs. A thorough understanding of potential roles of transporters in drug interactions and toxicity is important in drug development. The talk provided a high level overview of various transporter evaluation initiatives at the agency. Some of the topics discussed:
• On-going efforts on decision trees within the DDI guidance
• Novel emerging transporters impacting ADME
• Inter-play of hepatic transporters and liver-toxicity
• Inter-play of renal transporters and renal function
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
1. Journal reading
Dipeptidyl peptidase-4 inhibitors and
gallbladder or biliary disease in type 2 diabetes
Systematic review and pairwise and network
meta-analysis of randomised controlled trials
3. INTRODUCTION
Enhance the bioavailability of endogenous
glucagon-like peptide-1 and glucose dependent
insulinotropic polypeptide
Both of which might affect postprandial
gallbladder motility
Dipeptidyl
peptidase-
4 inhibitors
Type 2
diabetes
treatment
Risks of gallbladder or biliary
diseases (?)
Early studies have proposed
associations between gallbladder
related events and incretin based
drugs, including DPP-4 inhibitor
and GLP-1 receptor agonis
4. To evaluate the association between
DPP-4 inhibitors and gallbladder or
biliary diseases in patients with type 2
diabetes.
AIM
5. METHODS
Guideline : PRISMA and PRISMA extension for network meta-analysis
Design : Systematic review and Meta Analysis
Study sources, searches, and identification
Database : PubMed, the Cochrane Library, EMBASE and Web of Science,
Gray literature in Google Scholar and public repositories
Date : Up to 31 July 2021
Topics : Randomised controlled trials of DPP-4 inhibitors
Grouping : DPP-4 inhibitor & placebo → pairwise meta-analysis
DPP-4 inhibitor & other antidiabetes drug → network meta analysis
6. METHODS
Risk assessment : Cochrane risk of bias tool for randomized trials
Certainty of the evidence : Grading of Recommendations, Assessment,
Development and Evaluations framework
Deta extraction and quality assessment
Definition of outcome
The gallbladder or biliary diseases was identified on the basis of the
classifications in the Medical Dictionary for Regulatory Activities
(MedDRA) version 22.0.
7. METHODS
• Substantial heterogeneity was assessed by using χ2 tests
• Odds ratios and 95% confidence intervals was calculated by using fixed effect
models with the Mantel-Haenszel method
• Researcher evaluated absolute risk differences on the basis of the calculated odds
ratio and the mean event rate across the control groups for outcomes
• Publication bias was assessed by visual assessment of asymmetry of the funnel
plots and the Egger’s asymmetry test.
• Sensitivity analyses were carried out by using different pooling methods,24 using
random effect models
• Meta analysis was carried out with pairwise and network method. Results will be
presented with forest plot and league tables
• The meta, netmeta package in R (version 4.0.2) and Stata 15 was used for all
analyses.
Data synthesis and analysis
8. PRISMA flow
diagram
82 randomised controlled trials with
104.833 participants with type 2
diabetes in the traditional pairwise
meta-analysis
12. GRADE profile of DPP-4 inhibitors and risk of gallbladder or biliary diseases in patients
with type 2 diabetes compared with placebo or non-incretin drugs in pairwise meta-
analyses
13. RESULTS
Baseline characteristics
• The average age of participants was 59.4 years, and 39.7% (n=41 618) were female.
• The mean bodyBMI was 29.7, and mean HbA1c was 8.1%.
• Almost all trials documented gallbladder or biliary diseases as serious adverse
events.
Risk of bias and quality of evidence
• Sixty seven (82%) of 82 trials had low risks or some concerns of bias across all five
domains evaluated.
• The quality of evidence for outcomes in pairwise meta-analysis was rated as
moderate or low in the comparisons between DPP-4 inhibitors and placebo or non-
incretin drugs
14. Risks of cholecystitis, cholelithiasis, and biliary disease in patients
taking dipeptidyl peptidase-4 inhibitors
• There is a significant association between DPP-4 inhibitors and an increased risk of the
composite of gallbladder or biliary diseases (odds ratio 1.22) compared with placebo or
nonincretin drugs
• DPP-4 inhibitors significantly increased the risk of cholecystitis (odds ratio 1.43) but not of
cholelithiasis or biliary diseases
15. RESULTS
• DPP-4 inhibitors with a longer duration of treatment (≥26 weeks) were
significantly associated with increased risks of the composite of
gallbladder or biliary diseases (odds ratio 1.24) and cholecystitis
(1.51), but those with a shorter duration (<26 weeks) were not
Effects of duration of treatment, specific DPP-4
inhibitors, and types of control
• After use of different pooling methods and random effect models and
inclusion of double arm, zero events studies, the results did not
change for any outcomes.
Sensitivity analyses
17. RESULTS
Publication bias
• There is no publication bias observed in the included studies for the composite of
gallbladder or biliary diseases, cholelithiasis, cholecystitis, or biliary diseases when
Egger’s test was used
Comparisons between DPP-4 inhibitors, GLP-1 receptor
agonists, and SGLT-2 inhibitors in network meta analysis
• 184 trials in a network of comparisons among the three classes of antidiabetes drugs
were included
• DPP-4 inhibitors increased the risks of the composite of gallbladder or biliary
diseases (odds ratio 1.32, 1.06 to 1.64) and cholecystitis (1.55, 1.13 to 2.12)
compared with SGLT-2 inhibitors, as well as compared with placebo or other
antidiabetes drugs
18. Network plots of comparisons of DPP-4
inhibitors, glucagon-like peptide-1 (GLP-1)
receptor agonists, and sodiumglucose
cotransporter-2 (SGLT -2) inhibitors in
network meta-analyses
21. DISCUSSION
Comparison with other studies
● A retrospective study enrolled patients with
type 2 diabetes and reported no significant
associations between DPP-4 inhibitors and
an increased risk of gallbladder or biliary
diseases
● There is also some discrepancies between
this pooled results with some large scale
RCT like SAVOR-TIMI
• The risk of cholecystitis was higher with DPP-4 inhibitors
than with SGLT-2 inhibitors but similar to that with GLP-1
receptor agonists
Results from
this study
There is a difference in study
design
There is a difference in
population, periods of follow
up, specific DPP inhibitor
and reporting method
22. DISCUSSION
● The gallbladder or biliary effects of
DPP-4 inhibitors might be attributed
to the roles of GLP-1 and glucose
dependent insulinotropic polypeptide
● Glucose dependent insulinotropic
polypeptide was recently reported to
play a role in gallbladder relaxation
GLP-1 is involved in
impaired gallbladder
mobility and contractility
It inhibit the secretion of
cholecystokinin, which
also contribute to the
disease development
23. DISCUSSION
The longer DPP-4 inhibitor
treatment
The risk of gallbladder or
biliary disease increased
• A previous study did not observe the effects of sitagliptin on gallbladder
emptying,119 possibly owing to the short treatment duration (12 weeks).
• More importantly, as the duration of prescriptions for DPP-4 inhibitors is
usually longer in routine practice than in clinical trials
Awareness of the role of treatment duration might be of
great clinical importance
24. STRENGTHS OF STUDY
The first systematic review and meta analysis pooling the results of RCT to assess
the association between DPP-4 inhibitor and gallbladder or biliary disease
There is a possible effects of the duration of DPP-4 inhibitor treatment on
gallbladder or biliary disease
This study did a meta analysis comparing 3 antidiabetes drug
25. LIMITATIONS OF STUDY
The included studies were not specifically designed to evaluate
the effects of DPP-4 inhibitors on gallbladder or biliary disease
Gallbladder or biliary diseases were not predefined safety
outcomes in the included studies
Patient level data were inaccessible for the meta-analysis
26. POLICY IMPLICATIONS
● Dipeptidyl peptidase-4 inhibitors are
considered to have a good safety profile
● Concerns about potential adverse
events have usually focused on :
Heart failure
Bullous pemphigoids
Pancreatitis
Severe joint pain
This study highlights the
importance and raises
awareness of the risks of
cholecystitis
However, the overall absolute risk
increase was small (15 cases per
10.000 people per year)
US FDA has released warnings
about the risk of heart failure and
severe joint pain with DPP-4 inhibitor
27. CONCLUSIONS
DPP-4 inhibitors might increase the risk of
cholecystitis in patients with type 2 diabetes.
This findings suggest that physicians should be concerned about
increased risks of cholecystitis in patients with this particular
condition, especially those with longer treatment duration
We observed no significant between study heterogeneities, between design inconsistencies, or inconsistencies between direct and indirect treatment comparisons for all outcomes in the network metaanalysis
(supplementary tables N and O).
We observed no small study effects in the studies included in the network meta-analysis (supplementary figure I).
The quality of evidence for results from the network metaanalysis is shown in supplementary table P.
We observed no significant between study heterogeneities, between design inconsistencies, or inconsistencies between direct and indirect treatment comparisons for all outcomes in the network metaanalysis
(supplementary tables N and O).
We observed no small study effects in the studies included in the network meta-analysis (supplementary figure I).
The quality of evidence for results from the network metaanalysis is shown in supplementary table P.
This absolute risk increase should be weighed against the benefits of dipeptidyl peptidase-4 inhibitor treatment